HRP20191334T1 - Anti-fcrn antitijela - Google Patents

Anti-fcrn antitijela Download PDF

Info

Publication number
HRP20191334T1
HRP20191334T1 HRP20191334TT HRP20191334T HRP20191334T1 HR P20191334 T1 HRP20191334 T1 HR P20191334T1 HR P20191334T T HRP20191334T T HR P20191334TT HR P20191334 T HRP20191334 T HR P20191334T HR P20191334 T1 HRP20191334 T1 HR P20191334T1
Authority
HR
Croatia
Prior art keywords
fcrn
antibody
seq
fragment
binds
Prior art date
Application number
HRP20191334TT
Other languages
English (en)
Inventor
Helene Margaret Finney
Alastair David Griffi Lawson
Stevan Graham Shaw
Bryan John Smith
Kerry Louise Tyson
Lara KEVORKIAN
Christoph Meier
Paul Alan ATHERFOLD
Kaushik Sarkar
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46458733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191334(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HRP20191334T1 publication Critical patent/HRP20191334T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Claims (20)

1. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn koji se sastoji od teškog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 29 i lakog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 15.
2. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema patentnom zahtjevu 1, naznačen time, što je antitijelo scFv, Fv, Fab ili Fab' fragment.
3. Fab' fragment anti-FcRn antitijela prema patentnom zahtjevu 2 koji se sastoji od teškog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 36 i lakog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 22.
4. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema bilo kojem patentnom zahtjevu od 1 do 3, naznačen time, što je antitijelo ili vezujući fragment konjugiran na polimer, primjerice odabran iz škroba, albumina i polietilenglikola.
5. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema patentnom zahtjevu 4, naznačen time, što je polimer PEG, primjerice s molekularnom masom u rasponu od 5 do 50 kDa.
6. Anti-FcRn antitijelo prema patentnom zahtjevu 1, naznačen time, što je antitijelo antitijelo pune dužine, opcionalno naznačeno time, što je antitijelo pune dužine odabrano iz skupine koja se sastoji od IgG1, IgG4 i IgG4P.
7. Anti-FcRn antitijelo prema patentnom zahtjevu 6 koje se sastoji od teškog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 72 ili SEQ ID NO: 87 ili SEQ ID NO: 43 i lakog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 22.
8. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema patentnom zahtjevu 1, naznačen time, što je antitijelo ili njegov fragment koji se vezuje za FcRn Fab-dsFv koji se sastoji od teškog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 50 i lakog lanca koji sadrži sekvencu navedenu u SEQ ID NO: 46 ili SEQ ID NO: 78.
9. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema bilo kojem patentnom zahtjevu od 1 do 8, koji blokira vezivanje ljudskog IgG-a za ljudski FcRn.
10. Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema bilo kojem patentnom zahtjevu od 1 do 9, koji se ne vezuje za β2 mikroglobulin.
11. Izolirana DNK sekvenca koja šifrira teški/e i laki/e lanac/lance antitijela prema bilo kojem patentnom zahtjevu od 1 do 10.
12. Klonirajući ili ekspresijski vektor koji sadrži jednu ili više DNK sekvenci prema patentnom zahtjevu 11.
13. Vektor prema patentnom zahtjevu 12, naznačen time, što vektor sadrži (i) sekvencu navedenu u SEQ ID NO: 37 i sekvencu navedenu u SEQ ID NO: 23 ili (ii) sekvencu navedenu u SEQ ID NO: 80 i sekvencu navedenu u SEQ ID NO: 79 ili (iii) sekvencu navedenu u SEQ ID NO: 93 i sekvencu navedenu u SEQ ID NO: 91.
14. Domaćinska stanica za ekspresiju antitijela prema bilo kojem patentnom zahtjevu do 1 do 10, koja sadrži: i) DNK sekvencu koja šifrira teški lanac navedenog antitijela, i ii) DNK sekvencu koja šifrira laki lanac navedenog antitijela naznačena time, što se DNK sekvence nalaze u jednom ili više klonirajućih ili ekspresijskih vektora.
15. Domaćinska stanica prema patentnom zahtjevu 14 koja sadrži jedan ili više klonirajućih ili ekspresijskih vektora prema patentnom zahtjevu 13.
16. Farmaceutski pripravak koji sadrži anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn kako je definirano u bilo kojem patentnom zahtjevu od 1 do 10 u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa, razrjeđivača ili nosača.
17. Farmaceutski pripravak prema patentnom zahtjevu 16, koji dodatno sadrži druge djelatne sastojke.
18. Antitijelo ili njegov fragment koji se vezuje za FcRn kako je definirano u bilo kojem patentnom zahtjevu od 1 do 10 ili pripravak kako je definirano u patentnom zahtjevu 16 ili 17 za terapijsku primjenu.
19. Antitijelo ili njegov fragment koji se vezuje za FcRn kako je definirano u bilo kojem patentnom zahtjevu od 1 do 10 ili pripravak kako je definirano u patentnom zahtjevu 16 ili 17, za primjenu u liječenju autoimune bolesti, kao što je miastenija gravis, obični pemfigus, optički neuromijelitis, Guillan-Barreov sindrom, lupus i trombotična trombocitopenična purpura.
20. Antitijelo ili njegov fragment koji se vezuje za FcRn kako je definirano u bilo kojem patentnom zahtjevu od 1 do 10 ili pripravak kako je definirano u patentnom zahtjevu 16 ili 17, za primjenu u liječenju kronične upalne demijelinacijske polineuropatije (CIDP), paraproteinemičke polineuropatije, refraktorne epilepsije, ITP/TTP-a, hemolitičke anemije, Goodpastureovog sindroma, nekompatibilnosti krvnih grupa ABO, lupusnog nefritisa, bubrežnog vaskulitisa, sklerodermije, fibroznog alveolitisa, dilatirane kardiomiopatije, Graveove bolesti, dijabetesa tipa 1, autoimunog dijabetesa, pemfigusa, ANCA-pozitivnog vaskulitisa, dermatomiozitisa, Sjorgenove bolesti i reumatoidnog artritisa.
HRP20191334TT 2012-05-14 2019-07-23 Anti-fcrn antitijela HRP20191334T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208370A GB201208370D0 (en) 2012-05-14 2012-05-14 Antibodies
EP13725298.7A EP2850101B1 (en) 2012-05-14 2013-05-13 Anti-fcrn antibodies
PCT/EP2013/059802 WO2014019727A1 (en) 2012-05-14 2013-05-13 Anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
HRP20191334T1 true HRP20191334T1 (hr) 2019-10-18

Family

ID=46458733

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191334TT HRP20191334T1 (hr) 2012-05-14 2019-07-23 Anti-fcrn antitijela

Country Status (40)

Country Link
US (3) US10233243B2 (hr)
EP (2) EP2850101B1 (hr)
JP (4) JP6517140B2 (hr)
KR (2) KR102253090B1 (hr)
CN (1) CN104364265B (hr)
AP (1) AP2014008102A0 (hr)
AR (1) AR091036A1 (hr)
AU (3) AU2013298924B2 (hr)
BR (2) BR112014028457B1 (hr)
CA (2) CA2872326C (hr)
CL (1) CL2014003110A1 (hr)
CO (1) CO7151521A2 (hr)
CY (1) CY1121934T1 (hr)
DK (1) DK2850101T3 (hr)
EA (1) EA032770B1 (hr)
EC (1) ECSP14030789A (hr)
ES (1) ES2732081T3 (hr)
GB (1) GB201208370D0 (hr)
HK (1) HK1204627A1 (hr)
HR (1) HRP20191334T1 (hr)
HU (1) HUE045012T2 (hr)
IL (1) IL235042B (hr)
LT (1) LT2850101T (hr)
MA (1) MA37619B1 (hr)
ME (1) ME03415B (hr)
MX (1) MX365861B (hr)
NZ (1) NZ702457A (hr)
PE (2) PE20190229A1 (hr)
PH (1) PH12014502274A1 (hr)
PL (1) PL2850101T3 (hr)
PT (1) PT2850101T (hr)
RS (1) RS59072B1 (hr)
SG (1) SG11201406625XA (hr)
SI (1) SI2850101T1 (hr)
TN (1) TN2014000438A1 (hr)
TR (1) TR201910103T4 (hr)
TW (1) TWI598362B (hr)
UA (1) UA118954C2 (hr)
WO (1) WO2014019727A1 (hr)
ZA (1) ZA201407509B (hr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR102282134B1 (ko) 2013-04-29 2021-07-27 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
BR112016014810B1 (pt) 2013-12-24 2023-12-26 Argenx Bvba Antagonistas de fcrn e métodos de uso
EP3094648A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
HUE062403T2 (hu) 2014-04-30 2023-10-28 Hanall Biopharma Co Ltd FCRN-hez kötõdõ antistest autoimmun betegségek kezelésére
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
US10676526B2 (en) 2015-01-30 2020-06-09 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
CN106957364B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb12及其应用
KR20190015704A (ko) 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN109641957B (zh) * 2016-06-06 2022-10-04 希望之城 Baff-r抗体及其用途
EP3491025B1 (en) * 2016-07-29 2023-10-18 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
AU2018285577A1 (en) * 2017-06-15 2020-01-30 UCB Biopharma SRL Method for the treatment of immune thrombocytopenia
AU2018386193A1 (en) 2017-12-13 2020-06-25 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
KR20210078517A (ko) 2018-10-16 2021-06-28 유씨비 바이오파마 에스알엘 중증근무력증의 치료 방법
CA3118777A1 (en) * 2018-11-06 2020-05-14 Immunovant Sciences Gmbh Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
SG11202112010RA (en) 2019-06-07 2021-12-30 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
AU2020319897A1 (en) * 2019-08-01 2022-02-24 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
US20220280887A1 (en) 2019-08-02 2022-09-08 UCB Biopharma SRL Methods for purifying antibodies
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
CA3162074A1 (en) * 2020-01-10 2021-07-15 Joseph HORVATINOVICH Methods of treating tumors
TW202140560A (zh) * 2020-02-10 2021-11-01 大陸商北京拓界生物醫藥科技有限公司 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途
WO2022005113A1 (ko) * 2020-06-29 2022-01-06 한올바이오파마주식회사 항－ＦｃＲｎ 항체에 대한 제형
US20230406924A1 (en) 2020-11-02 2023-12-21 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
WO2023013618A1 (ja) * 2021-08-02 2023-02-09 国立研究開発法人国立長寿医療研究センター ヒトアストロウイルスの感染レセプターとその応用
CN113484526A (zh) * 2021-08-11 2021-10-08 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
KR20240036076A (ko) * 2021-08-13 2024-03-19 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Fcrn을 특이적으로 인식하는 항체 및 이의 용도
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2063975C3 (de) 1970-12-28 1973-09-27 Deutsche Vergaser Gmbh & Co Kg, 4040 Neuss Brennstoffzumeßduse mit temperatur abhangig veränderbarem Austrittsquer schnitt fur Vergaser insbesondere Gleich druckvergaser, fur Brennkraftmaschinen
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
BR0315012B1 (pt) * 2002-10-04 2013-05-28 montagem de painel de toque para um dispensador de bebida, e, mÉtodo para aumentar uma interface de usuÁrio.
ATE528648T1 (de) 2002-12-03 2011-10-15 Ucb Pharma Sa Verfahren zum nachweis antikörper-herstellender zellen
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0506912D0 (en) * 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
WO2006118772A2 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
CN101268372A (zh) * 2005-07-21 2008-09-17 根马布股份公司 与fc受体结合的抗体药物的药效测定
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
ZA200804337B (en) * 2005-11-28 2009-11-25 Genmab As Recombinant monovalent antibodies and methods for production thereof
EP1986690A4 (en) * 2006-01-25 2009-05-13 Univ New York State Res Found ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
BRPI0814763A2 (pt) 2007-08-09 2015-03-03 Syntonix Pharmaceuticals Inc Peptídeos imunomoduladores
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
BR122021026834B1 (pt) * 2008-04-25 2022-11-08 Takeda Pharmaceutical Company Limited Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn
US20100048488A1 (en) 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
DK2334705T3 (en) 2008-09-26 2017-03-27 Ucb Biopharma Sprl BIOLOGICAL PRODUCTS
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
MX343659B (es) 2011-06-02 2016-11-16 Dyax Corp Proteínas de unión receptoras fc.
SG11201401649VA (en) 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof
KR20130071961A (ko) 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products

Also Published As

Publication number Publication date
JP2015525204A (ja) 2015-09-03
PH12014502274B1 (en) 2014-12-10
ME03415B (me) 2020-01-20
PL2850101T3 (pl) 2019-10-31
IL235042B (en) 2019-05-30
KR20210014761A (ko) 2021-02-09
KR20150005987A (ko) 2015-01-15
CN104364265B (zh) 2019-07-16
ZA201407509B (en) 2016-02-24
EA201492101A1 (ru) 2015-04-30
AR091036A1 (es) 2014-12-30
AU2018205057A1 (en) 2018-07-26
IL235042A0 (en) 2014-12-31
AU2018205057B2 (en) 2020-05-21
CA2872326A1 (en) 2014-02-06
US11384148B2 (en) 2022-07-12
PH12014502274A1 (en) 2014-12-10
MX365861B (es) 2019-06-18
US20150118240A1 (en) 2015-04-30
JP7221000B2 (ja) 2023-02-13
PE20150002A1 (es) 2015-01-28
HUE045012T2 (hu) 2019-11-28
CO7151521A2 (es) 2014-12-29
TR201910103T4 (tr) 2019-08-21
AU2013298924A1 (en) 2015-01-15
PT2850101T (pt) 2019-07-23
CA2872326C (en) 2020-10-13
TW201350505A (zh) 2013-12-16
EA032770B1 (ru) 2019-07-31
PE20190229A1 (es) 2019-02-13
EP3527588A1 (en) 2019-08-21
SG11201406625XA (en) 2014-12-30
CY1121934T1 (el) 2020-10-14
MA37619A1 (fr) 2016-01-29
CA3089517C (en) 2022-10-04
AP2014008102A0 (en) 2014-12-31
ES2732081T3 (es) 2019-11-20
AU2018205057B9 (en) 2020-10-22
JP7050115B2 (ja) 2022-04-07
SI2850101T1 (sl) 2019-08-30
LT2850101T (lt) 2019-08-12
CN104364265A (zh) 2015-02-18
AU2013298924B2 (en) 2018-05-10
JP2020168003A (ja) 2020-10-15
JP6517140B2 (ja) 2019-05-22
US20230074381A1 (en) 2023-03-09
DK2850101T3 (da) 2019-07-15
GB201208370D0 (en) 2012-06-27
EP2850101B1 (en) 2019-05-01
KR102344901B1 (ko) 2021-12-28
KR102253090B1 (ko) 2021-05-18
CL2014003110A1 (es) 2015-06-19
MX2014012890A (es) 2014-11-14
BR112014028457B1 (pt) 2023-04-04
JP2018183151A (ja) 2018-11-22
US20190248890A1 (en) 2019-08-15
EP2850101A1 (en) 2015-03-25
RS59072B1 (sr) 2019-09-30
US10233243B2 (en) 2019-03-19
ECSP14030789A (es) 2015-09-30
HK1204627A1 (en) 2015-11-27
MA37619B1 (fr) 2017-07-31
CA3089517A1 (en) 2014-02-06
NZ702457A (en) 2016-09-30
BR122020023791B1 (pt) 2023-04-04
BR112014028457A2 (pt) 2017-06-27
TN2014000438A1 (en) 2016-03-30
UA118954C2 (uk) 2019-04-10
AU2020217370A1 (en) 2020-09-03
TWI598362B (zh) 2017-09-11
WO2014019727A1 (en) 2014-02-06
JP2022104938A (ja) 2022-07-12

Similar Documents

Publication Publication Date Title
HRP20191334T1 (hr) Anti-fcrn antitijela
HRP20192006T1 (hr) Antitijela specifična za fcrn
HRP20191219T1 (hr) Molekule protutijela koje imaju specifičnost za ljudski ox40
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
HRP20200174T1 (hr) Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba
HRP20201377T1 (hr) Vezujuće molekule specifične za il-21 i njihova upotreba
JP2018512138A5 (hr)
JP2017504578A5 (hr)
JP2019519527A5 (hr)
RU2016146486A (ru) Гуманизированные антитела против cd269 (bcma)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2015118063A (ru) Иммуномодулирующие белки
JP2017522043A5 (hr)
JP2014518883A5 (hr)
JP2012501669A5 (hr)
JP2012516158A5 (hr)
CA2849765C (en) Hybrid constant regions
JP2012143232A5 (hr)
JP2017511130A5 (hr)
US20210171624A1 (en) Anti-interferon gamma antibodies and uses thereof
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
JP2010227116A5 (hr)
JP2012531922A5 (ja) Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位
JP2018537421A5 (hr)
JP2016536322A5 (hr)